ZLAB is a Chinese biotech company specializing in the treatment of cancer, among other things. In December an insider bought 4,000 shares. Also, hedge funds have been increasing their exposure to ZLAB for the last 4 quarters. The stop is 7% below at the red line. There are 2 upper trend lines (yellow). My feeling is that ZLAB will be unsuccessful at getting through both of these levels of resistance. However, they are about 31% above. This is a more than 4:1 reward/risk ratio. Also note that ZLAB has earnings on Mar 1 after hours. 87M float on this one
免责声明
这些信息和出版物并非旨在提供，也不构成TradingView提供或认可的任何形式的财务、投资、交易或其他类型的建议或推荐。请阅读使用条款了解更多信息。
免责声明
这些信息和出版物并非旨在提供，也不构成TradingView提供或认可的任何形式的财务、投资、交易或其他类型的建议或推荐。请阅读使用条款了解更多信息。